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THE BIOCHEMICAL RATIONALE FOR NORMOBARIC HYPEROXIA 
TREATMENT OF RETINAL DISORDERS 
CHRISTOPHER HSU 
ABSTRACT 
Purpose: Ischemic retinopathies such as diabetic retinopathy (DR), retinal vein 
occlusions (RVO), and age-related macular degeneration (AMD) are ocular diseases 
caused by abnormal changes in the microvasculature that results in ischemia. This is 
often followed by a secondary phase characterized by pathological neovascularization 
and leakage of fluid, which contributes to a loss of visual acuity in affected patients. 
Anti-VEGF therapy, the current standard of treatment for ischemic retinopathies, is 
invasive, costly, and lacks a known treatment period. Supplemental oxygen provides the 
therapeutic potential of not only oxygenating hypoxic retinal cells, but also reducing the 
neovascularization and edema associated with many ischemic retinopathies through the 
downregulation of proangiogenic and pro-inflammatory cytokines.The objective of this 
study is to understand the biochemical underpinnings of treating ischemic retinopathies 
with hyperoxia. The elucidation of the effect hyperoxia on the molecular level may help 
guide the development of future studies regarding this novel treatment. 
Methods: 68 undiluted vitreous samples were obtained during pars plana vitrectomy 
(PPV) and the concentration analysis of 34 proteins was analyzed using the Bio-Plex Pro 










Results: Numerous growth factors and inflammatory cytokines were significantly 
upregulated between the non-DM and PDR groups - Angiopoietin-2, EGF, Endoglin, G-
CSF, HB-EGF, HGF, PDGF, PIGF, sHER2/neu,	TIE-2, VEGF-A, VEGF-D, IL-18, IL-6, 
IL-8, PECAM-1, sCD40L, SCF, sFASL, sIL-6Ra, TNF-⍺, Leptin, PAI-1, and uPA. 	
A literature search of these proteins revealed many to be directly activated by HIF-1 
transcription factor, which is the “master switch” for genes transcribed during a hypoxic 
event.  
Conclusion: The abundance of proangiogenic and pro-inflammatory factors in PDR that 
are also upregulated by HIF-1 demonstrate the potential for using hypoxia to treat PDR 
(and other ischemic retinopathies) through the reduction of HIF-1. This study also shows 
the wide variability in the expression levels of these proteins which helps provide a better 
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The retina is considered the most metabolically active tissue in the human body 
due to the high energy cost of phototransduction, neurotransmitter exocytosis, and 
protein/ion transport by photoreceptors (Wong-Riley, 2010). Impairment of the retinal 
blood supply is associated with numerous retinopathies, and often adversely impacts 
retinal function and consequently, vision. In patients with retinal detachment (RD), 
hypoxia caused by the physical separation of photoreceptors from the underlying choroid 
leads to photoreceptor degeneration (Lewis et al., 2004). Although reattachment surgery 
can successfully repair the retina anatomically, vision acuity is not always restored due to 
the loss of photoreceptor structural integrity during the ischemic period (Put et al., 2014). 
Hypoxia also plays a causative role in diseases such as proliferative diabetic retinopathy 
(PDR), exudative (wet) age-related macular degeneration (AMD), and retinal vein 
occlusions (RVO) by upregulating expression of vascular endothelial growth factor 
(VEGF), a potent promoter of neovascularization and vascular leakage (Linsenmeier & 
Zhang, 2017). Anti-VEGF medications have revolutionized the treatment of these 
conditions in recent years due to their efficacy in reducing pathological angiogenesis and 
edema. However, the invasive nature, cost, and lack of a known treatment period of anti-
VEGF therapeutics are a burden to patients and healthcare institutions (Zhao & Singh, 
2018). More importantly, accumulating data suggest that an abundance of 
cytokines/chemokines other than VEGF contribute to the pathogenesis of ischemic 




treatments (Bolinger & Antonetti, 2016). Therefore, there is a need to consider an 
alternative treatment that can be used adjunctively with anti-VEGF agents or by itself to 
improve the management of retinal diseases.  
 Supplemental oxygen, or hyperoxia, directly targets the hypoxic nature of retinal 
detachments and ischemic retinopathies by supplying the retina with a higher 
concentration of inspired oxygen. In addition, hyperoxia may diminish expression levels 
of numerous proangiogenic and pro-inflammatory factors by reducing the activation of 
hypoxia-inducible factor 1 (HIF-1) – the “master switch” of oxygen homeostasis 
(Arjamaa & Nikinmaa, 2006). Previous research has demonstrated the potential of 
hyperoxia in reducing photoreceptor death after a RD and decreasing macular thickness 
in patients with diabetic macular edema (DME); however, a deeper understanding of the 
effectiveness of hyperoxia has yet to be established (Mervin et al., 1999; Nguyen et al., 
2004). This study investigates the biochemical rationale for the normobaric hyperoxia 
treatment of retinopathies in an ongoing pilot study conducted at the Beth Israel 
Deaconess Medical Center.  
 
1. Significance of Oxygen for Retinal Function 
  A dysregulation of the oxygen supply to the retina often leads to a loss of retinal 
function due to the critical role that oxygen plays in supporting the high metabolic 
demand of the retina (Linsenmeier & Padnick–Silver, 2000). While low oxygen tissue 
levels can contribute to retinopathy, excessive amounts of oxygen lead to an increased 




result, maintenance of oxygen levels and a healthy vascular network are necessary to 
support optimal retinal function. 
1.1 Anatomy of the Retina 
 Located posterior to the vitreous cavity of the eye, the retina is a multilayered 
structure that converts incoming light into electrical signals that the brain can process 
(Figure 1). The major cellular components of the retina are the photoreceptors, retinal 
pigment epithelium (RPE) cells, interneuron cells, ganglion cells, and glial cells. The 
photoreceptor layer, which harbors the rods and cones, is responsible for the process of 
phototransduction (Figure 2). Rods exhibit a high sensitivity to light and mediate vision 
Figure 1 – Cells and Layers of the Retina. Illustrated above are the cellular 
components of the retina, organizational layers, and the retinal and choroidal 





in dim environments while cones have a comparatively low sensitivity to light and 
contribute to high acuity color vision. In the human retina, rods comprise 95% of all 
photoreceptors and dominate the peripheral retina while cones account for 5% and are 
concentrated within the fovea (Narayan et al., 2017). The four main structural regions of 
each photoreceptor are the synaptic terminal, cell body, mitochondria-containing inner 
segment, and an outer segment that contains visual pigment responsible for light 
absorption. 
 RPE cells are joined together by 
tight junctions and collectively form the 
outer blood-retina barrier (BRB), a 
physiological barrier that separates the 
choriocapillaris from the photoreceptors 
(Narayan et al., 2017). Interneurons, 
which include bipolar, amacrine, 
horizontal, and interplexiform cells, are 
located within the inner nuclear layer and 
transmit electrical signals emitted from 
the photoreceptors to the ganglion cells. 
The ganglion cells convey electrical 
information from the retina to the rest of the 
brain. Their axons congregate at the optic 
disk and exit the eye as the optic nerve. 
Figure 2 – Structural Anatomy of 
Photoreceptors. Rods and cones have 
four main structural regions: outer 
segment (OS), inner segment (IS), cell 
body (CB), and synaptic terminal 





Finally, the four glial cell types – Muller cells, astrocytes, microglia, and 
oligodendrocytes – collectively function to maintain an optimal local environment 
(Joussen et al., 2007). 
1.2 Retinal and Choroidal Circulation 
 The blood supply of the retina is provided by the retinal and choroidal 
vasculatures. The retinal circulation, which is derived from the central retinal artery, 
consists of three parallel yet interconnected vascular plexuses – the superficial, inner, and 
deep plexus (Figure 1). Together they vascularize the inner retina (Eshaq et al., 2014). On 
the other hand, the choroidal circulation is supplied by the long and short posterior ciliary 
arteries and forms a single layer of densely arranged fenestrated capillaries called the 
choriocapillaris. Located immediately behind the retina, the choroid supplies blood to the 
avascular outer retina (photoreceptors and RPE) (Eshaq et al., 2014). This unique dual 
blood supply circumvents the dilemma of blood vessels positioned directly anterior to the 
photoreceptor outer segments, which would interrupt light absorption (Narayan et al., 
2017). However, the two circulations are non-overlapping, thus making the retina 
vulnerable to either retinal or choroidal ischemia.  
 The choroidal circulation is characterized by a high flow rate (estimated 
1400ml/100g per minute) and low O2 extraction (<1 vol %) (Linsenmeier & Padnick–
Silver, 2000). The combination of these two factors generates a large enough O2 gradient 
between the choroid and outer retina to sustain the high metabolic demand of the 
photoreceptor inner segments (Linsenmeier & Padnick–Silver, 2000). Changes in the 




choroid and photoreceptor inner segments alter the O2 consumption of photoreceptors. 
For example, a study has shown that a 100µm retinal detachment lowers the average O2 
consumption of the outer retina to 34% of that in a healthy individual (Linsenmeier & 
Padnick–Silver, 2000). In contrast, the retinal circulation exhibits a low blood flow rate 
and high O2 extraction (40-50 vol %) similar to that of the rest of the brain (Bill & 
Sperber, 1990). Here, a large O2 flux such as that associated with the choroidal 
circulation is unnecessary due to the proximity of the retinal capillary plexuses to the 
inner retinal cells (Bill & Sperber, 1990).  
 The regulation of the two vasculatures also differ significantly. The retinal 
circulation is controlled by autoregulation and responds to changes in hydrostatic 
pressure and fluctuations in O2, CO2, pH, and temperature (P. A. Campochiaro, 2000). 
During hyperoxia, the retinal circulation theoretically vasoconstricts and maintains inner 
retinal PO2 levels close to that at air breathing. However, hypercapnia superimposed on 
hyperoxia may reduce the autoregulatory constriction of retinal vessels (Yu et al., 2007). 
On the other hand, the choroidal circulation is not auto-regulated such that its regulation 
is independent of local metabolic factors (Bill & Sperber, 1990). Instead, it is strongly 
innervated by the autonomic nervous system and responds to systemic changes (P. A. 
Campochiaro, 2000). Under hyperoxia, the PO2 of the choriocapillaris increases and 
enhances the O2 flux to the outer retina (Linsenmeier & Zhang, 2017). 
1.3 Energy Consumption of Photoreceptors 
 Neuronal activity is tightly coupled with energy metabolism, especially so with 




oxidase, the terminal enzyme of the electron transport chain and a measure of oxidative 
capacity, reveal intense labeling throughout the inner segments of photoreceptors – an 
indication of mitochondrial abundance (Wong-Riley, 2010). ATP generated by the inner 
segments fuel major ATP-consuming activities within the photoreceptor, primarily the 
active transport of ions and glutamate release at synaptic terminals (Narayan et al., 2017).  
 It is important to note that photoreceptor energy consumption is also light-
dependent (Figure 3). During darkness, cation channels in photoreceptor outer segments 
open and create a large inward gradient of ions known as the dark current (Ramsey & 
Arden, 2015). The partial depolarization resulting from the influx of cations propagates 
glutamate release from the synapses. In addition, Na+K+ ATPases located in the inner 
segment transmembrane actively pump out the excess Na+ to maintain the dark current. 
Figure 3 – Energy Consumption in Darkness and Illumination. The metabolic 
demand and oxygen consumption required to sustain the dark current and glutamate 




This cycle of continuous neurotransmitter release and Na+K+ ATPase activation 
consumes large amounts of ATP produced in the inner segments. During illumination, 
photoreceptors engage in phototransduction, which converts photons into electrical 
signals through a signal transduction cascade and causes closure of cation channels in the 
outer segment. These processes also consume energy but are relatively small compared to 
that in the dark current (Ramsey & Arden, 2015). In the rods of mice, ATP expenditure is 
estimated to be 9*107 ATP s-1 in darkness and only 2*107 ATP s-1 under illumination 
(Wong-Riley, 2010). In fact, there is evidence that the dark current exacerbates hypoxia 
in ischemic retinal diseases due to its toll on the oxidative capacity of the receptor 
(Ramsey & Arden, 2015). Thus, sufficient blood flow and oxygen delivery through the 
retinal/choroidal circulations are critical for retinal function due to the high metabolic 
demand of the eye.  
 
2. Rationale of Hyperoxia as a Potential Treatment 
 Hypoxia is implicated in the pathogenesis of numerous retinal diseases, although 
the mechanisms through which they manifest varies (Linsenmeier & Zhang, 2017). As a 
result, the treatment efficiency of supplemental oxygen could fluctuate depending on the 
type of retinal disorder and the method in which ischemia is induced. Previous research 
has sought to elucidate the role of hypoxia in different retinopathies – RD, RVO, AMD, 
PDR – and some clinical studies have investigated the potency of hyperoxia in improving 
functional and anatomical outcomes.  




 Diabetic retinopathy (DR) is the most frequent complication of diabetes and the 
leading cause of blindness in the developed world (Al-Shabrawey et al., 2015). There are 
two main groups of DR – non-proliferative diabetic retinopathy (NPDR) is characterized 
by increased vascular permeability, microaneurysms, and intraretinal hemorrhages while 
proliferative diabetic retinopathy (PDR) is marked by additional neovascularization 
(Figure 4) (Joussen et al., 2007).  One of the initial abnormalities of DR is the decrease of 
retinal perfusion caused by a vasoconstriction of arteries (Semeraro et al., 2015). Retinal 
pericyte loss is another characteristic feature of DR that contributes to retinal ischemia by 
causing endothelial cell damage and capillary destabilization (Semeraro et al., 2015). The 
resulting hypoxic state induces biochemical alterations that include an upregulation of 
vascular endothelial growth factor (VEGF) and secretion of pro-inflammatory cytokines 
(Linsenmeier & Zhang, 2017). VEGF, in particular, is a critical player during hypoxia 
due to its potency in mediating retinal angiogenesis and the breakdown of the BRB 
(Arjamaa & Nikinmaa, 2006). Ultimately, the hyperpermeability of the abnormal blood 
vessels and disruption of the BRB could lead to an accumulation of intraretinal and 
subretinal fluid known as diabetic macular edema (DME), which is a major cause of 
vision regression among diabetic patients.  
 One pilot study treated diabetic patients suffering from chronic DME with three 
months of supplemental oxygen (4 L/min of O2), and observed reductions in macular 
thickness and improvements in visual acuity (Nguyen et al., 2004). In another study, 
diabetic subjects that were on 100% oxygen exhibited improvements in contrast 




In addition, Harris et al (1996) found that retinal blood flow was not diminished in 
diabetic subjects after hyperoxia, which indicates that diabetic patients may have an 
impaired autoregulatory capacity. Therefore, patients with DR may experience increased 
benefits from supplemental oxygen due to the lack of hyperoxia-induced vasoconstriction 














           
2.2 Oxygen and Retinal Vein Occlusions 
 Retinal vein occlusions (RVO) involve an obstruction of venous return from the 
retinal circulation (Khayat et al., 2018). Classically, RVO is broken down into central 
Figure 4 – Fluorescein Angiography of PDR Patient. The abnormal 
growth of new vessels and the resulting edema are indicated by the red 




retinal vein occlusion (CRVO) if the obstruction occurs within the central retinal vein, or 
a branch retinal vein occlusion (BRVO) if any tributary is obstructed (Ip & Hendrick, 
2018). After the thrombus has formed, retinal blood flow decreases and autoregulation 
increases intravenous hydrostatic pressure, causing damage to vascular endothelial cells 
and increasing vascular permeability (Khayat et al., 2018). This results in retinal 
hemorrhages and macular edema, both of which contribute to vision impairment. In 
addition, the increased intravenous hydrostatic pressure could decrease the pressure 
difference across capillary networks, causing capillary nonperfusion and retinal hypoxia 
(Khayat et al., 2018). The ischemic retina upregulates VEGF production prompting 
neovascularization, which frequently leads to numerous vision-threatening complications 
(Joussen et al., 2007). However, retinal oximetry and comparisons of oxygen saturation 
in RVO patients have demonstrated that ischemia is not associated with all patients with 
RVO for reasons that are not yet fully understood (Hardarson & Stefánsson, 2012). As 
such, risk of neovascularization is 35% in ischemic RVO patients compared with 10% in 
the non-ischemic counterparts (Ip & Hendrick, 2018).  
 Supplemental oxygen may be beneficial in treating RVO due to the reduced blood 
flow and increased VEGF production associated with the disease. There is, however, 
limited literature on the effects of hyperoxia on RVO. One study investigated the effects 
of  hyperbaric hyperoxia on miniature pigs with experimental BRVO and found that the 
resulting choroidal O2 gradient was high enough to supply O2 to the ischemic inner retina 
(Pournaras et al.,1990).   




 Age-related macular degeneration (AMD) involves the degeneration of the central 
retina and is classified into two clinical forms – non-exudative/dry AMD and 
exudative/wet AMD (Stefánsson et al., 2011). Dry AMD, which accounts for 85% of all 
cases, is characterized by drusen and loss of photoreceptors while the hallmark of wet 
AMD is choroidal neovascularization (Vadlapatla et al., 2013). Measurements of oxygen 
tension have demonstrated that choroidal blood circulation is diminished in both wet and 
dry AMD, and that the loss of choroidal perfusion is positively correlated with AMD 
severity (Metelitsina et al., 2008). In addition to the ischemic choroid, it has been 
suggested that drusen formation and thickening of the Bruch’s membrane in dry AMD 
also impair the diffusion of O2 from the choriocapillaris to the photoreceptors (Stefánsson 
et al., 2011). For wet AMD, hypoxia induces VEGF release from RPE cells, which 
causes choroidal neovascularization (and leakage of fluid) into the subretinal space 
through a break in Bruch’s membrane (Peter A. Campochiaro, 2015). Hyperoxia may 
benefit AMD patients in two ways – it could increase diffusion of O2 from the choroid to 
the photoreceptors and lower the production of VEGF and other proangiogenic factors to 
reduce choroidal neovascularization.  
2.4 Oxygen and Retinal Detachment 
 RD is characterized by a separation of the retina from the underlying RPE, and 
the most common form of RD – rhegmatogenous retinal detachment – is caused by a tear 
in the retina that allows leakage of fluid from the vitreous cavity to the subretinal space 
(Put et al., 2014). The increased distance between the retina and the underlying choroidal 




photoreceptor apoptosis and subsequently, the loss of mitochondria in the inner segments 
and the degeneration of outer segments (Vadlapatla et al., 2013). 
 Mathematical models have suggested that supplemental oxygen increases 
choroidal oxygen tension and the O2 flux to the inner segments to compensate for the 
poor diffusion during a RD (Linsenmeier & Padnick–Silver, 2000). In addition, feline 
and squirrel models with surgically-induced RD have demonstrated improved 
photoreceptor survivability after treatment with 70% oxygen (Lewis et al., 2004; Sakai, 
Lewis, Linberg, & Fisher, 2001). As a result, patients with RD could benefit from 
hyperoxia between diagnosis and the scheduled reattachment surgery to limit 
photoreceptor apoptosis (Mervin et al., 1999). 
 
3. Biochemical Underpinnings of Hyperoxia Treatment 
 Retinal cells are sensitive to fluctuations in oxygen tension and employ intricate 
mechanisms to adjust to sudden deviations in PO2. The hypoxia-inducible factor (HIF-1) 
is a transcriptional regulator that plays a central role in mediating the cellular changes 
following oxygen deprivation (Vadlapatla et al., 2013). Under hypoxic conditions, HIF-1 
is activated and upregulates the expression of various genes, many of which contribute to 
the development and progression of retinal pathologies such as DR, AMD, and 
BRVO/CRVO (Linsenmeier & Zhang, 2017). Of the numerous HIF-1 downstream 
products, VEGF has garnered the most attention due to its role as a potent angiogenic and 
vascular permeabilization factor in many retinal disorders (Gao et al., 2017). Although 




neovascularization, there are other proangiogenic and pro-inflammatory factors activated 
by HIF-1 that are unaffected by VEGF inhibitors (Iwase et al., 2013). Since HIF-1 is 
activated by hypoxia, supplemental oxygen could reduce the expression of HIF-1 in 
patients with ischemic retinal disorders. By targeting this common denominator in 
hypoxia-induced events and reducing the transcription of its downstream effectors, there 
is a possibility of achieving greater efficacy than with VEGF inhibitor treatments alone.  
3.1 Regulation of HIF-1 
 HIF-1 is a heterodimeric protein consisting of two subunits – HIF-1a and HIF-1b 
(Hong et al., 2004). During normal oxygen perfusion, HIF-1a is heavily hydroxylated 
and binds to the von Hippel-Lindau disease (VHL) protein, which targets it for ubiquitin-
mediated proteasomal degradation (Figure 5)(Joussen et al., 2007). When cells are 
hypoxic, HIF-1a is not hydroxylated and freely dimerizes with the constitutively 
expressed HIF-1b, forming the HIF-1 complex (Joussen et al., 2007). The assembled 
HIF-1 transcription factor then translocates into the nucleus and activates an array of 
hypoxia-inducible genes responsible for regulating energy metabolism, angiogenesis, cell 
cycle, and apoptosis (Arjamaa & Nikinmaa, 2006). As a result, oxygen plays a critical 
role in regulating the function of HIF-1 through the post-translational modification of 
HIF-1a.  
3.2 Vascular Endothelial Growth Factor 
VEGF, a 48 kDa homodimeric glycoprotein, is an endothelial cell mitogen and 




retinal vessel architecture (Cheng et al., 2017). But in many retinal diseases, VEGF 
release promotes pathological angiogenesis that features permeable vessels susceptible to 
leakage of fluid (Campochiaro, 2015). Studies have demonstrated that VEGF expression 
is elevated in retinopathies involving ocular neovascularization, including PDR, wet 
AMD, and ischemic CRVO/BRVO (Joussen et al., 2007). The hemorrhaging and fluid 
leakage from these abnormal blood vessels distort vision and can eventually lead to the 
formation of scar tissue (Bolinger & Antonetti, 2016). 
Figure 5 – HIF-1a Regulation is Oxygen Dependent. During normoxia, HIF-
1a is hydroxylated and degraded by proteasomes, preventing the assembly of 
HIF-1 heterodimer. In hypoxia, HIF-1a is not hydroxylated and freely binds to 
HIF-1b forming HIF-1, which activates downstream effectors. Figure taken from 




 The approval of anti-VEGF treatments by the FDA in 2004 has been monumental 
in improving the prognosis of patients with neovascular retinopathies (Zhao & Singh, 
2018). However, more studies are beginning to indicate that a significant number of 
patients with pathological angiogenesis do not respond to anti-VEGF treatments, which 
suggests the involvement of non-VEGF mediators in the pathogenesis of these retinal 
diseases (Bolinger & Antonetti, 2016).  
3.3 Pro-inflammatory Cytokines 
 It is widely accepted that inflammation assumes an important role in retinopathies 
such as DR and AMD (Semeraro et al., 2015). In DR, the release of inflammatory 
molecules including ICAM-1, TNF-a, IL-1, and COX-2 contributes to the degeneration 
of retinal capillaries (Semeraro et al., 2015). Other pro-inflammatory cytokines such as 
IL-6 and IL-8 may also contribute to neovascularization and enhance leukocyte adhesion 
to the endothelium (Semeraro et al., 2015). Using rat models of DR, one research group 
observed that the onset of HIF-1a expression is closely correlated with the upregulation 
of IL-6, IL-1b, and TNF-a and suggest that the targeted inhibition of HIF-1a could lower 
the levels of these cytokines (Gao et al., 2017). Another study found that in HIF-1a 
knockout mice, ICAM-1 expression was significantly attenuated, while vascular leakage 
and neovascularization were reduced as well (Lin et al., 2011). These results not only 
indicate that inflammatory cytokines are potent mediators in the pathophysiology of 
many retinopathies, but also that HIF-1 inhibition may be a viable therapeutic option.  




 Erythropoietin (EPO) is usually produced in the kidneys and triggers the synthesis 
of red blood cells in the event of hypoxia (Arjamaa & Nikinmaa, 2006). However, in the 
event of acute retinal hypoxia, EPO is also expressed through a HIF-1 mediated 
mechanism and functions to induce retinal angiogenesis (Arjamaa & Nikinmaa, 2006). In 
fact, retinal EPO stimulates neovascularization in PDR independently of VEGF, which 
could explain cases of patients who do not respond to anti-VEGF treatment (Watanabe et 
al., 2005). Suppression of both EPO and VEGF also inhibited neovascularization to an 
extent greater than that achieved by each compound alone (Takagi et al., 2007).  
 In addition, apoptotic signaling events contribute to photoreceptor cell death 
following retinal ischemia, which can impair visual prognosis even after successful 
treatment (Linsenmeier & Padnick–Silver, 2000). In cases of RD, most photoreceptor 
apoptosis occurs 1 to 3 days post-detachment and is regulated by caspase activation 
(Yang et al., 2004). Similarly, caspase-dependent apoptosis of ganglion cells occurs soon 
after developing DR resulting in progressive impairment of visual acuity (Adamiec-
Mroczek et al., 2015). In a recent study, Caspase-3 – an indicator of cellular apoptosis – 
was found to be elevated in retinal tissues in a rat model of DR (Gao et al., 2017). 
Furthermore, inhibition of retinal HIF-1a significantly reduced expression levels of 
Caspase-3, which strongly suggests the involvement of HIF-1a in the apoptotic pathway 
(Gao et al., 2017). As a result, hyperoxia treatment may also reduce retinal cell apoptosis 
by attenuating HIF-1 activation after ischemic insult.  
 Some other growth factors implicated in the pathogenesis of ischemic 




(bFGF), placental growth factor (PGF), and angiopoietin-2 (ANGPT2) (Iwase et al., 
2013; Semeraro et al., 2015). Furthermore, chemokines such as monocyte 
chemoattractant protein-1 (MCP-1) and stromal cell-derived factor (SDF-1) stimulate the 
migration of leukocytes to endothelial cells, which further enhances fibrosis and 
angiogenesis (Semeraro et al., 2015). While there is still much to be uncovered about the 
involvement of proangiogenic and pro-inflammatory factors in the pathogenesis of retinal 
diseases, many are transcriptionally regulated by HIF-1 (Figure 6) (Takagi et al., 2007).   
 Instead of approaching the matter by implementing a combined cocktail of 
specific inhibitors to target these molecules, the inhibition of upstream HIF-1 may 
achieve the same effect with more convenience and efficacy. One study delivered a HIF-
Figure 6 – Target Genes Transcriptionally Activated by HIF-1. Figure taken from 




1 inhibitor (Digoxin) intraocularly into a mouse model of choroidal neovascularization 
and found significantly reduced levels of HIF-1 target genes and a regression of ocular 
neovascularization (Iwase et al., 2013). Through the attenuation of HIF-1 and its 
associated effector genes, supplemental oxygen could offer a more cost-effective and 





















Aims and Objectives: 
  The purpose of this study was to investigate the benefits of hyperoxia in treating 
ischemic retinopathies (RD, PDR, RVO, AMD) and to provide a biochemical 
justification of the treatment through the analysis of vitreous mediators in PDR patients. 
We hypothesized that through the enhanced delivery of oxygen to retinal cells and 
reduction of proangiogenic/pro-inflammatory factors, supplemental oxygen can improve 







This study was a combination of an ongoing pilot study of hyperoxia treatment 
and a retrospective analysis of vitreous mediators extracted from PDR patients. The aim 
is to evaluate the treatment of ischemic retinopathies with supplemental oxygen through 
the biochemical analysis of proangiogenic/pro-inflammatory factors in PDR patients. The 
following methods and data analysis details the collection and analysis of the vitreous 
samples obtained from patients who underwent vitrectomy, and was adapted from 
Kovacs et al., 2015.   
 
Study Population 
 Undiluted vitreous samples were collected from 68 eyes of 68 patients who 
underwent pars plana virectomy (PPV) performed by Jorge Arroyo, MD, MPH, at the 
Beth Israel Deaconess Medical Center between November 2010 and September 2012. 
Patients who underwent PPV for epiretinal membrane peeling (ERMP)/Macular Hole 
(MH) or PDR were included in the analysis, while those who underwent surgery for other 
conditions were excluded. Clinical consent was obtained from each patient for sample 
collection. 
 
Vitreous Collection, Storage, and Analysis 
 During PPV, undiluted vitreous and serum samples were extracted and collected 
from the patients with a biopsy technique detailed in Arroyo et al., 2005. In general, 




to obtain a 0.5- to 1-ml undiluted vitreous sample. A 3-ml syringe on a three-way 
stopcock facilitated the manual aspiration of the vitreous specimen. Once an adequate 
amount of vitreous was obtained, the infusion was turned on and the stopcock was rotated 
to proceed with the vitrectomy. The undiluted vitreous specimens were then immediately 
placed into a cold storage freezer that was maintained at -80˚C. The samples were 
subsequently shipped overnight on dry ice to Schepens Eye Research Institute (Boston, 
MA, USA) for analysis with the Bio-Plex Pro Human Cancer Biomarker Assay.  
 The Bio-Plex Pro Human Cancer Biomarker Assay is a magnetic bead-based 
assay that accurately quantifies a mixture of 34 biomarkers involved in disease 
mechanisms including angiogenesis, metastasis, cell proliferation, cell 
adhesion/migration, apoptosis, and inflammation. The analyzed proteins consist of 
Angiopoietin-2, EGF, Endoglin, FGF, Follistatin, GCSF, HB-EGF, HGF, IGFBP, IL-6, 
IL-8, IL-18, Leptin, Osteopontin, PAI-1, PDGF, PECAM-1, PlGF, Prolactin, sCD40L, 
SCF, sEGFR, sFASL, sHER2/neu, sIL-6Ra, sVEGF-R1, sVEGF-R2, TGF-alpha, TIE-2, 
TNF-alpha, uPA, VEGFa, VEGFc, VEGFd. The concentrations of proteins were reported 
in picograms per millimeter.  
 To set up the assay, vitreous samples were thawed, the Bio-Plex machine was 
calibrated, and the lasers of the equipment were pre-warmed for 4 hours. The standards 
were reconstituted with 781µL standard diluent, and the controls were reconstituted with 
250µL standard diluent. After vortexing the bottles for 5 seconds, they were iced for 30 
minutes. During this 30-minute icing period, the 6.5-µm magnetic beads were prepared 




5472µL Assay Buffer and 288µL beads were added to a 15-mL tube, and each well was 
filled with 50µL of this solution and shaken. After the 30-minute icing period, the 
samples were diluted with a 4-fold standard dilution series and 50µL standards, blanks, 
controls, and samples were added to each. The plate was then covered with adhesive plate 
sealer and foil and was shaken while incubating for 1 hour. Ten minutes prior to the 
completion of this incubation, the detection antibodies were vortexed for 5 seconds and 
145µL detection Assay Buffer was added along with 2755µL Assay Buffer diluent. Once 
the 1-hour incubation was complete and the plate was washed three times, 25µL of this 
diluted detection antibody solution was added to each well and the plate was once again 
covered and shaken while incubating for 30 minutes.  
 The Stretavidin-PE (SA-PE) stock solution was prepared 10 minutes prior to the 
completion of this incubation period. The SA-PE solution was covered with foil and 
vortexed for 5 seconds prior to adding 60µL SA-PE as well as 5940µL Assay Buffer to a 
separate vial. After the incubation period, the plate was washed with antibodies three 
times and 50µL diluted, vortexed SA-PE solution was added to each well. The plate was 
once again incubated for 10 minutes then washed three times with antibodies. The 
magnetic beads were resuspended in 125µL Assay Buffer and added to each well of the 
plate, which was then shaken for 30 seconds. After removing the plate sealer, the Bio-
Plex Machine then read the plate to record measurements for each of the 34 biomarkers.  
 All multiplex assay components, including the validation kits, calibration kits, and 
human Bio-Plex Pro Human Cancer Biomarker Assay Panels 1 and 2 were purchased 




run cleanly, and the results reflect the dilution factor of 1. Samples, standards, blank, and 
controls were run in duplicate on the multicytokine suspension array system (Bio-Plex; 
Bio-Rad Laboratories), as suggested by the manufacturer's protocol. Vortex-diluted (×1) 
magnetic coupled beads were first added to each well of the assay plate, followed by a 
plate washing (×2) with Uwash buffer (Bio-Rad Laboratories). Samples, standards, blank, 
and controls (50 µL) are added to each well according to the plate layout and incubated in 
the dark for an hour at room temperature with vigorous shaking. Between each incubation 
period, washing of the plate follows immediately (×3). Detection antibodies (×1) are 
added to the plate, with a 30-minute incubation period, followed by the addition of 
Streptavidin-PE (×1) for 10 minutes with shaking. After the final wash, the magnetic 
beads are resubmerged in assay, incubated, and shook for 30 seconds before the plate is 


























 Angiopoietin-2, EGF, Endoglin, FGF, G-CSF, HB-EGF, HGF, IGFBP, PDGF, 
PIGF, sEGFR, sHER2/neu, sVEGFR-1, sVEGFR-2, TGF⍺,	TIE-2, VEGF-A, VEGF-C, 
and VEGF-D were labeled as “growth factors” due to properties that stimulate cellular 
growth, proliferation, and differentiation. IL-18, IL-6, IL-8, PECAM-1, sCD40L, SCF, 






Assembled in Table 1 is a list of the vitreous biomarkers and their respective 
mean concentrations (pg/mL) found in each of the three categories – non-DM, DM, and 
PDR groups. Table 2 displays Mann-Whitney U test P values for comparative analysis of 
vitreous mediators between the non-DM and DM group (1 and 2), DM and PDR group (2 
and 3), and the non-DM and PDR group (1 and 3). Comparison of vitreous proteins 
between the non-DM and DM cohort revealed elevated Endoglin, G-CSF, PIGF, VEGF-
D, IL-6, and sCD40L. Between the DM and PDR group, several biomarkers were also 
enhanced, including PIGF, VEGF-A, IL-8, and Leptin. Comparison of the PDR to the 
non-DM group yielded elevated concentrations among numerous (1) growth factors: 
Angiopoietin-2, EGF, Endoglin, G-CSF, HB-EGF, HGF, PDGF, PIGF, sHER2/neu,	TIE-







Biomarker Type Biomarker Non-DM DM PDR 
Growth Factor Angiopoietin-2 128.4 260.7 1389.7 
 EGF 2.5 3.3 3.2 
 Endoglin 16.8 35.9 42.4 
 FGF-Basic 73.7 73.2 67.2 
 G-CSF 15.2 110.9 29.8 
 HB-EGF 1.1 3.2 2.9 
 HGF 5399.4 5070.1 8711.7 
 IGFBP-1 409.8 713.7 583.9 
 PDGF 23.2 25.6 31.9 
 PIGF 3.5 13.9 42.7 
 sEGFR 2043.5 2938.5 2429.1 
 sHER2/neu 289.1 485.3 466.7 
 sVEGFR-1 1113.3 1145.8 573.5 
 sVEGFR-2 2039.0 1383.6 2222.2 
 TGF⍺ 2.4 3.2 2.8 
 TIE-2 1748.7 1654.7 1499.7 
 VEGF-A 36.0 260.8 518.8 
 VEGF-C 73.4 100.9 96.4 
 VEGF-D 58.8 87.9 90.8 
Inflammatory Cytokines IL-18 7.6 11.7 39.4 
 IL-6 17.3 579.7 170.3 
 IL-8 5.7 56.4 34.3 
 PECAM-1 376.3 414.1 486.8 
 sCD40L 6.9 19.4 18.2 
 SCF 46.2 61.2 58.2 
 sFASL 10.3 18.1 19.0 
 sIL-6Ra 277.1 541.1 605.4 
 TNF-⍺ 2.2 3.7 4.6 
Other Biomarkers Follistatin 101.1 210.7 134.5 
 Leptin 280.3 348.2 1285.8 
 Osteopontin 39881.3 30186.1 33348.5 
 PAI-1 2878.5 6657.2 13731.2 
 Prolactin 460.0 457.5 470.9 
 uPA 135.8 284.2 275.4 
Table 1. Mean Concentration (pg/mL) of Biomarkers Across non-DM, DM, and 









   
Biomarker Type Biomarker 1 and 2 2 and 3 1 and 3 
Growth Factor Angiopoietin-2 .166 .223 .000 
  EGF .180 .777 .009 
  Endoglin .013 .676 .000 
  FGF-Basic .850 .832 .811 
  G-CSF .005 .167 .043 
  HB-EGF .052 .620 .000 
  HGF .668 .052 .003 
  IGFBP-1 .973 .167 .069 
  PDGF .460 .490 .011 
  PIGF .003 .007 .000 
  sEGFR .571 .777 .114 
  sHER2/neu .440 .860 .003 
  sVEGFR-1 .605 .254 .007 
  sVEGFR-2 .850 .887 .714 
  TGF⍺ .855 .851 .673 
  TIE-2 .295 .915 .064 
  VEGF-A .133 .013 .000 
  VEGF-C .304 .939 .063 
  VEGF-D .021 .958 .001 
Inflammatory Cytokines IL-18 .483 .080 .002 
  IL-6 .007 .620 .000 
  IL-8 .137 .037 .000 
  PECAM-1 .345 .416 .001 
  sCD40L .004 .983 .000 
  SCF .571 .915 .048 
  sFASL .073 .750 .038 
  sIL-6Ra .061 .645 .001 
  TNF-⍺ .085 .366 .001 
Other Biomarkers Follistatin .154 .167 .170 
  Leptin .525 .026 .000 
  Osteopontin .172 .937 .038 
  PAI-1 .255 .073 .000 
  Prolactin .797 .887 1.000 
  uPA .096 .524 .002 
Table 2. Mann-Whitney U Test P Values for Biomarker Comparison. Shown 
below are the P values for comparing biomarker concentrations between different 
sampling groups. 1= non-DM, 2=DM, 3=PDR. Statistical significance denoted by 




sCD40L, SCF, sFASL, sIL-6Ra, and TNF-⍺, and (3) other biomarkers: Leptin, PAI-1, 
and uPA (Table 1). Markedly lower concentrations for sVEGFR-1 and Osteopontin were 
observed for comparisons between PDR and non-DM (Table 1). 
 
Vitreous Biomarkers that are HIF-1 Effector Genes  
The shaded biomarkers in Table 1 and 2 represent genes that are directly 
upregulated by HIF-1 during hypoxia based on current literature (Gao et al., 2017; Peet, 
Kittipassorn, Wood, Chidlow, & Casson, 2017; Takagi et al., 2007; Vadlapatla et al., 
2013). These include Angiopoietin-2, EGF, Endoglin, IGFBP-1, PDGF, PIGF, sVEGF-
R1, sVEGF-R2, TGF-⍺,	VEGF-A, VEGF-C, VEGF-D, IL-6, IL-8, SCF, TNF-⍺, Leptin, 
PAI-1. Between the non-DM and DM group, only Endoglin, PIGF, VEGF-D, and IL-6 
were significantly elevated as HIF-1 target effectors. Comparisons of the non-DM to 
PDR group show that all HIF-1 target effectors mentioned above had statistically 
significant changes other than IGFBP-1, sVEGF-R2, TGF-⍺, and VEGF-C.  
Figure 7 represents the percentage change in concentrations of HIF-1 inducible 
vitreous biomarkers between non-DM patients and PDR patients. The included 
biomarkers also demonstrated statistically significant change on Table 2. Of these 
biomarkers, all exhibited a positive percentage change with the exception of SVEGFR-1, 
which had a 48% decrease in concentration between the non-DM group and PDR group. 
In addition, numerous vitreous mediators had levels that increased multifold, with 




displaying a percentage change greater than 100%. VEGF-A displayed the greatest 



















An Evaluation of PDR Biomarkers 
 The results of this study provide a snapshot of the numerous proangiogenic and 
pro-inflammatory factors that are expressed in PDR (Table 1). In addition, the biomarkers 
tested in this assay are representative of a wide-range of disease mechanisms, including 
angiogenesis, metastasis, cell proliferation, cell adhesion/migration, apoptosis, and 
inflammation, which underscores the multidimensional pathophysiology of ischemic 
retinopathies such as PDR. The exponential increase of certain proteins from the non-DM 
(control) to DM group, and from the non-DM to PDR group indicates the significant role 
that they play in diabetes and PDR. Some of these mediators are well-validated in the 
current literature, such as VEGF, Angiopoietin-2, and PDGF, while others have been less 
documented.  
Leptin is most recognized as an anti-obesity hormone that is synthesized in 
response to high intracellular triglycerides. Interestingly, leptin seems to also participate 
in the development of PDR since in the current study, leptin levels were shown to have 
increased by 359% when comparing between the non-DM and PDR groups (Figure 7). 
One study showed that in a mouse model of ischemia-induced retinopathy, 
overexpression of leptin stimulated neovascularization (Suganami et al., 2004). Although 
the exact mechanism for leptin production has yet to be defined, it is known to be a target 
effector of HIF-1 (Vadlapatla et al., 2013). 
Another notable finding was PIGF, placental growth factor, which was the only 




in Table 2. PIGF is a homolog of VEGF and interacts with VEGF’s receptor – VEGF-R1- 
to enact angiogenic and mitogenic effects (Ziche et al., 1997). PIGF levels were also 
found to be enhanced in vitreous samples of PDR patients and correlated with the 
expression of VEGF (Mitamura et al., 2002). This current study also demonstrates that 
PIGF is upregulated in diabetics without PDR due to the statistically significant 
difference in PIGF concentration between the DM and PDR groups (Table 2). Knockout 
of PIGF in a diabetic mouse strain has been shown to prevent the development of PDR 
and also reduce the expression of HIF1 and VEGF (Huang et al., 2015). As a result, 
PIGF’s synergy with VEGF as well as its strong expression in both diabetes (without 
PDR) and PDR highlights its importance as a target for inhibition.  
 
Implications for Hyperoxia Treatment 
 The upregulation of a myriad of growth factors and inflammatory cytokines in 
PDR suggests that inhibiting multiple proteins could achieve more efficacy in attenuating 
the disease than blocking just one – as is the case with anti-VEGF treatments. Although 
the vitreous biomarkers of other retinopathies such as AMD and CRVO/BRVO were not 
analyzed in the study, it could be assumed that many of the same proteins are also 
involved due to the ischemic nature of these diseases.  
 The potential benefit of hyperoxia for patients with ischemic retinopathies 
(including RD, AMD, PDR, and RVO) lies upon its ability to deliver a higher 
concentration of oxygen to the photoreceptors and to limit the expression of various 




HIF-1 is the master regulator of many of the proteins involved in the pathogenesis of 
ischemic retinopathies and is activated by hypoxia, the usage of supplemental oxygen 
could reduce its activation and thus, downregulate the expression of pathological 
cytokines.  
 This study demonstrated a surge in the concentrations of proangiogenic and pro-
inflammatory cytokines when comparing between vitreous samples of non-DM and PDR 
patients (Table 2). More importantly, a great proportion of these factors is regulated by 
HIF-1. An analysis of the biomarkers that are both significantly elevated in PDR and 
upregulated by HIF-1 shows the extent of gene expression that can be induced during 
retinal ischemia (Figure 7).  
As expected, VEGF exhibited the greatest change in concentration (1340% 
increase) from non-DM to PDR eyes, which highlights the reason anti-VEGF 
therapeutics are still the standard of treatment for PDR-induced neovascularization and 
edema (Figure 7). However, figure 7 also shows other growth factors with similar levels 
of heightened expression in PDR. These include Angiopoietin-2 (983% increase) and 
PIGF (1112% increase), both of which are known to promote angiogenesis and vascular 
permeability (Khalaf et al., 2017). A reduction of HIF-1 through hyperoxia could lower 
the expression of these growth factors in addition to VEGF.  
Inflammatory cytokines including IL-6, IL-8, and TNF-⍺ are also found to be 
substantially upregulated in PDR with increases in concentration of 886%, 504%, and 
104%, respectively, when compared to levels in non-DR patients. Il-6 and Il-8 are potent 




(Bolinger & Antonetti, 2016; Gao et al., 2017). Although the role of inflammation in 
inducing neovascularization is widely accepted, there are very few treatment options 
available that target inflammatory molecules in ischemic retinopathies (Zhang et al., 
2011). Supplemental oxygen may be a great candidate for diminishing the expression of 
pro-inflammatory cytokines and limiting their pathological effect by deactivating HIF-1.  
 
Limitations  
 Certain limitations in the present study should be discussed to improve future 
research. One limitation is the biomarker assay, which only screens for 34 growth factors 
and cytokines. A greater selection of biomarkers could reveal additional findings about 
the pathogenesis of PDR. In addition, since the goal of the experiment is to justify the 
treatment of hyperoxia with patients diagnosed with different ischemic retinopathies (RD, 
AMD, RVO, PDR), vitreous samples representative of non-PDR patients should be 
collected such that comparative analysis of mediator concentrations could be made. 
Lastly, although a sufficient number of eyes were analyzed, they were not evenly 
distributed across the three cohorts, which could have skewed some results. As a result, 
future prospective studies should include a relatively even number of vitreous samples 
that spans across a spectrum of ischemic retinal diseases. Other assays could also be 








 In conclusion, the analysis of growth factors and pro-inflammatory cytokines in 
PDR patients revealed many noteworthy findings about the underlying molecules 
responsible for the pathogenesis of ischemic retinopathies. Furthermore, the involvement 
of numerous HIF-1 inducible genes helps elucidate the biomolecular mechanism in which 
supplemental oxygen can be beneficial to patients with PDR, RD, RVO, or AMD. Future 
studies will be necessary to confirm the extent in which hyperoxia can attenuate the 
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